Advanced searches left 3/3

Metastatic Pancreatic Adenocarcinoma - DOAJ

Summarized by Plex Scholar
Last Updated: 19 May 2022

* If you want to update the article please login/register

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma

In pancreatic ductal adenocarcinoma, maintenance therapy is only rarely considered. This is the first report of maintenance nivolumab after a fruitful multimodality therapy in metastatic PDAC, to date.

Source link: https://doi.org/10.3389/fimmu.2022.870406


Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study

In patients with metastatic pancreatic adenocarcinoma, it was necessary to determine the efficacy and toxicity of irinotecan, oxaliplatin, and S-1. Patients and methods: Patients with cytologically or histologically confirmed metastatic pancreatic adenocarcinoma underwent surgery on day 1 and oxaliplatin 85 mg/m 2 intravenous infusion on day 1 and then stopped a treatment regimen on day 1 and 14, repeating the regimen every 21 days until one of the following occurred: disease progression, intolerable toxicity, or patient death. The median OS was 11. 01 months [95% confidence interval : 2. 83–5. 88] and the median PFS was 4. 33 months [95% confidence interval : 2. 83–5. 88]. Patients with Grade 3 or 4 neutropenia and thrombocytopenia were found in 29. 27% and 12. 20% of the patients, respectively. Irinotecan, oxaliplatin, and S-1 is a safe and effective treatment for metastatic pancreatic adenocarcinoma, and any toxicities are mild to moderate and tolerable.

Source link: https://doi.org/10.1177/1758835920970843


Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group

Background: Liposomal irinotecan plus 5-fluorouracil and leucovorin was safe and well tolerated in patients with metastatic pancreatic adenocarcinoma, which was the cause of adenocarcinoma treatment with gemcitabine-based therapy in the global NAPOLI-1 trial. In clinical research, real-world data may help clarify the effects and safety profile of nal-IRI + 5-FU/LV. Methods: This retrospective review included patients with mPAC who received nal-IRI + 5-FU/LV after gemcitabine-based therapy in Korea under a Managed Access Program. Conclusion: Real-life data for Korean patients reveals that nal-IRI + 5-FU/LV, as NAPOLI-1, is safe and well-tolerated in patients with mPACs who progressed on gemcitabine-based therapy.

Source link: https://doi.org/10.1177/1758835919871126


Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis

Abstract Background: Most patients with ductal pancreatic adenocarcinoma are diagnosed with locally advanced or metastatic disease. Results Mean survival time was 38. 41 weeks, with a median life expectancy of 27. 00 weeks. Patients treated with palliative surgery and chemotherapy had 6. 7 times lower risk of death in comparison to patients without any treatment. Patients with a ploidy score > 3. 6 had a 5. 3 times higher risk of death in comparison to patients with ploidy score 2. 2 – 3. 6, and those with a 3. 2-fold higher risk of death had 5. 3 times higher risk of death than those with a 2. 2-3. 6 average.

Source link: https://doi.org/10.1186/1471-2407-9-264


Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis

Abstract Background The paperback Themestatic pancreatic adenocarcinoma has a short median overall survival of 5 to 6 months. Adenocarcinoma patients with metastatic or recurrent pancreatic adenocarcinoma were diagnosed with single-agent gemcitabine and had an OS longer than one year, according to our researchers. 1 clinical/demographic information age, gender, ECOG PS, number, and location of metastatic sites; 2 Laboratory results Hematocrit, hemoglobin, glucose, LDH, renal and liver function; and CA19-9 are among the four outcomes diagnostic codes, which include: 1 clinical/demographic determinants, TTF, renal and liver disease; and 2 year-OS. The difference between 9. 0 to 14. 3 months was between Median OS and TTF on gemcitabine, which was 26. 9 95%. After chemotherapy with gemcitabine, a subgroup of patients with metastatic pancreatic cancer has prolonged survival.

Source link: https://doi.org/10.1186/1756-8722-2-13


Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.

In patients with metastatic non-treated pancreatic adenocarcinoma, a random multicenter phase II trial was carried out to determine the sequential therapy approach employing FOLFIRI. 3 and gemcitabine alternately, as well as gemcitabine alone in patients with metastatic non-treated pancreatic adenocarcinoma. With a PFS rate of 42. 5 percent in Arm 2 at 6 months, it concludes that the sequential treatment program appears to be cost-effective and efficient. HRQoL was measured at baseline and every two months until the end of the study or death as a secondary endpoint of this research. This paper presents the results of this longitudinal review of the health-related quality of life. Patients of Arm 2 received a longer QFS of Global Health Status, emotional stability, and pain in a longer QFS than those of Arm 1. Arm 2 patients received a longer QFS with a longer QFS than those of Arm 1.

Source link: https://doi.org/10.1371/journal.pone.0125350


Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

Abstract Background The combination of gemcitabine and nab-paclitaxel has improved clinical success than gemcitabine alone. It's unknown if this combination therapy is used at first line in advanced pancreatic adenocarcinoma. Methods A total of 125 patients were randomized to combination therapy and single-agent gemcitabine arms for 7 of 8 weeks, as well as the first 3 of four weeks, before progression or severe toxicity. QoL scores in the third month QoL scores remained unchanged, with 34 and 58. 3% of cases in gemcitabine and gemcitabine+nab-P arms showing no deterioration. Median progression free survivors in these treatment arms were 6. 28 and 3. 22 months, respectively. Conclusions: Combination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. In addition, combination therapy raised response rate without irritation or deteriorated QoL. For advanced pancreatic cancer, a combination therapy with gemcitabine and nab-paclitaxel may be able to provide significant relief.

Source link: https://doi.org/10.1186/s12885-020-06758-9


A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

Abstract Background The goal of the present research was to determine the efficacy and safety profile of gemcitabine-based regimens in the treatment of locally advanced and metastatic pancreatic adenocarcinoma. The results showed that gemcitabine-based combination therapy was associated with improved overall survival, transition-free survival, and overall response rate than gemcitabine monotherapy. However, no survival benefit was apparent when the gemcitabine-cisplatin combination was compared to gemcitabine monotherapy. The combination of gemcitabine and other cytotoxic agents achieved similar results. In this case, there were no differences between the OS and PFS; rather than gemcitabine alone; however, our analysis indicated that the ORR improved when patients were treated with the gemcitabine-camptothecin combination rather than gemcitabine alone; however, there were no differences between the OS and PFS. Conclusions Gemcitabine, capecitabine or oxaliplatin, along with increased OS and ORR in monotherapy when compared to gemcitabine in monotherapy, which is expected to become the standard first-line therapy of LA/MPC.

Source link: https://doi.org/10.1186/1756-8722-4-11


First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis

The objective was to compare and rank the locally developed and metastatic pancreatic adenocarcinoma chemotherapy regimens from randomized controlled trials over the past 15 years.

Source link: https://doaj.org/article/e614e31b574948128d31f9f8f24c4234


Isolated metastatic pancreatic adenocarcinoma to the uterine cervix: A case report

We encountered a case of recurrent pancreatic adenocarcinoma presenting as a solitary metastasis to the cervix. For diagnosing metastatic disease to the cervix, the clinician and pathologist must also consider his biological counterparts, such as the newly described gastric-type endocervical adenocarcinoma. Surgery may be helpful to the cervix of metastatic disease.

Source link: https://doi.org/10.1016/j.gore.2019.07.003

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions